Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology 2023 Focused Update of the Guidelines for the Use of Antiplatelet Therapy

Antiplatelet therapy (APT) is the foundation of treatment and prevention of atherothrombotic events in patients with atherosclerotic cardiovascular disease. Selecting the optimal APT strategies to reduce major adverse cardiovascular events, while balancing bleeding risk, requires ongoing review of c...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of cardiology Vol. 40; no. 2; pp. 160 - 181
Main Authors: Bainey, Kevin R., Marquis-Gravel, Guillaume, Belley-Côté, Emilie, Turgeon, Ricky D., Ackman, Margaret L., Babadagli, Hazal E., Bewick, David, Boivin-Proulx, Laurie-Anne, Cantor, Warren J., Fremes, Stephen E., Graham, Michelle M., Lordkipanidzé, Marie, Madan, Mina, Mansour, Samer, Mehta, Shamir R., Potter, Brian J., Shavadia, Jay, So, Derek F., Tanguay, Jean-François, Welsh, Robert C., Yan, Andrew T., Bagai, Akshay, Bagur, Rodrigo, Bucci, Claudia, Elbarouni, Basem, Geller, Carol, Lavoie, Andrea, Lawler, Patrick, Liu, Shuangbo, Mancini, John, Wong, Graham C.
Format: Journal Article
Language:English
Published: England Elsevier Inc 01.02.2024
Subjects:
Acute Coronary Syndrome - drug therapy
Canada
Cardiology
Humans
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors
Systematic Reviews as Topic
Treatment Outcome
Canada
ISSN:0828-282X, 1916-7075, 1916-7075
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Antiplatelet therapy (APT) is the foundation of treatment and prevention of atherothrombotic events in patients with atherosclerotic cardiovascular disease. Selecting the optimal APT strategies to reduce major adverse cardiovascular events, while balancing bleeding risk, requires ongoing review of clinical trials. Appended, the focused update of the Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology guidelines for the use of APT provides recommendations on the following topics: (1) use of acetylsalicylic acid in primary prevention of atherosclerotic cardiovascular disease; (2) dual APT (DAPT) duration after percutaneous coronary intervention (PCI) in patients at high bleeding risk; (3) potent DAPT (P2Y12 inhibitor) choice in patients who present with an acute coronary syndrome (ACS) and possible DAPT de-escalation strategies after PCI; (4) choice and duration of DAPT in ACS patients who are medically treated without revascularization; (5) pretreatment with DAPT (P2Y12 inhibitor) before elective or nonelective coronary angiography; (6) perioperative and longer-term APT management in patients who require coronary artery bypass grafting surgery; and (7) use of APT in patients with atrial fibrillation who require oral anticoagulation after PCI or medically managed ACS. These recommendations are all on the basis of systematic reviews and meta-analyses conducted as part of the development of these guidelines, provided in the Supplementary Material. Le traitement antiplaquettaire est la base du traitement et de la prévention des manifestations athérothrombotiques chez les patients atteints d’une maladie cardiovasculaire athéroscléreuse. Le choix du traitement antiplaquettaire approprié pour réduire les événements cardiovasculaires indésirables majeurs, tout en tenant compte du risque de saignement, demande un suivi constant des essais cliniques. En annexe, la mise à jour ciblée des lignes directrices de la Société cardiovasculaire du Canada/Association canadienne de cardiologie d’intervention pour l’utilisation du traitement antiplaquettaire formule des recommandations sur les sujets suivants : 1) l’emploi de l’acide acétylsalicylique dans la prévention primaire des maladies cardiovasculaires athéroscléreuses; 2) la durée de la bithérapie antiplaquettaire après une intervention coronarienne percutanée (ICP) chez les patients qui présentent un risque élevé de saignement; 3) le choix d’une bithérapie antiplaquettaire puissante (inhibiteur de P2Y12) chez les patients qui présentent un syndrome coronarien aigu et les stratégies éventuelles de désescalade de la bithérapie antiplaquettaire après une ICP; 4) le choix et la durée de la bithérapie antiplaquettaire chez les patients atteints du syndrome coronarien aigu qui reçoivent un traitement médical sans revascularisation; 5) le prétraitement par une bithérapie antiplaquettaire (inhibiteur de P2Y12) avant une coronarographie non urgente ou urgente; 6) la prise en charge par un traitement antiplaquettaire périopératoire et à long terme chez les patients qui ont besoin d’un pontage aortocoronarien; et 7) l’utilisation du traitement antiplaquettaire chez les patients qui présentent une fibrillation auriculaire et qui ont besoin d’un traitement anticoagulant par voie orale après une ICP ou qui présentent un syndrome coronarien aigu traité médicalement. Toutes les recommandations reposent sur les analyses des publications et les méta-analyses menées dans le but de formuler ces lignes directrices, fournies dans le matériel supplémentaire.
AbstractList Antiplatelet therapy (APT) is the foundation of treatment and prevention of atherothrombotic events in patients with atherosclerotic cardiovascular disease. Selecting the optimal APT strategies to reduce major adverse cardiovascular events, while balancing bleeding risk, requires ongoing review of clinical trials. Appended, the focused update of the Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology guidelines for the use of APT provides recommendations on the following topics: (1) use of acetylsalicylic acid in primary prevention of atherosclerotic cardiovascular disease; (2) dual APT (DAPT) duration after percutaneous coronary intervention (PCI) in patients at high bleeding risk; (3) potent DAPT (P2Y12 inhibitor) choice in patients who present with an acute coronary syndrome (ACS) and possible DAPT de-escalation strategies after PCI; (4) choice and duration of DAPT in ACS patients who are medically treated without revascularization; (5) pretreatment with DAPT (P2Y12 inhibitor) before elective or nonelective coronary angiography; (6) perioperative and longer-term APT management in patients who require coronary artery bypass grafting surgery; and (7) use of APT in patients with atrial fibrillation who require oral anticoagulation after PCI or medically managed ACS. These recommendations are all on the basis of systematic reviews and meta-analyses conducted as part of the development of these guidelines, provided in the Supplementary Material. Le traitement antiplaquettaire est la base du traitement et de la prévention des manifestations athérothrombotiques chez les patients atteints d’une maladie cardiovasculaire athéroscléreuse. Le choix du traitement antiplaquettaire approprié pour réduire les événements cardiovasculaires indésirables majeurs, tout en tenant compte du risque de saignement, demande un suivi constant des essais cliniques. En annexe, la mise à jour ciblée des lignes directrices de la Société cardiovasculaire du Canada/Association canadienne de cardiologie d’intervention pour l’utilisation du traitement antiplaquettaire formule des recommandations sur les sujets suivants : 1) l’emploi de l’acide acétylsalicylique dans la prévention primaire des maladies cardiovasculaires athéroscléreuses; 2) la durée de la bithérapie antiplaquettaire après une intervention coronarienne percutanée (ICP) chez les patients qui présentent un risque élevé de saignement; 3) le choix d’une bithérapie antiplaquettaire puissante (inhibiteur de P2Y12) chez les patients qui présentent un syndrome coronarien aigu et les stratégies éventuelles de désescalade de la bithérapie antiplaquettaire après une ICP; 4) le choix et la durée de la bithérapie antiplaquettaire chez les patients atteints du syndrome coronarien aigu qui reçoivent un traitement médical sans revascularisation; 5) le prétraitement par une bithérapie antiplaquettaire (inhibiteur de P2Y12) avant une coronarographie non urgente ou urgente; 6) la prise en charge par un traitement antiplaquettaire périopératoire et à long terme chez les patients qui ont besoin d’un pontage aortocoronarien; et 7) l’utilisation du traitement antiplaquettaire chez les patients qui présentent une fibrillation auriculaire et qui ont besoin d’un traitement anticoagulant par voie orale après une ICP ou qui présentent un syndrome coronarien aigu traité médicalement. Toutes les recommandations reposent sur les analyses des publications et les méta-analyses menées dans le but de formuler ces lignes directrices, fournies dans le matériel supplémentaire.
Antiplatelet therapy (APT) is the foundation of treatment and prevention of atherothrombotic events in patients with atherosclerotic cardiovascular disease. Selecting the optimal APT strategies to reduce major adverse cardiovascular events, while balancing bleeding risk, requires ongoing review of clinical trials. Appended, the focused update of the Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology guidelines for the use of APT provides recommendations on the following topics: (1) use of acetylsalicylic acid in primary prevention of atherosclerotic cardiovascular disease; (2) dual APT (DAPT) duration after percutaneous coronary intervention (PCI) in patients at high bleeding risk; (3) potent DAPT (P2Y inhibitor) choice in patients who present with an acute coronary syndrome (ACS) and possible DAPT de-escalation strategies after PCI; (4) choice and duration of DAPT in ACS patients who are medically treated without revascularization; (5) pretreatment with DAPT (P2Y inhibitor) before elective or nonelective coronary angiography; (6) perioperative and longer-term APT management in patients who require coronary artery bypass grafting surgery; and (7) use of APT in patients with atrial fibrillation who require oral anticoagulation after PCI or medically managed ACS. These recommendations are all on the basis of systematic reviews and meta-analyses conducted as part of the development of these guidelines, provided in the Supplementary Material.
Antiplatelet therapy (APT) is the foundation of treatment and prevention of atherothrombotic events in patients with atherosclerotic cardiovascular disease. Selecting the optimal APT strategies to reduce major adverse cardiovascular events, while balancing bleeding risk, requires ongoing review of clinical trials. Appended, the focused update of the Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology guidelines for the use of APT provides recommendations on the following topics: (1) use of acetylsalicylic acid in primary prevention of atherosclerotic cardiovascular disease; (2) dual APT (DAPT) duration after percutaneous coronary intervention (PCI) in patients at high bleeding risk; (3) potent DAPT (P2Y12 inhibitor) choice in patients who present with an acute coronary syndrome (ACS) and possible DAPT de-escalation strategies after PCI; (4) choice and duration of DAPT in ACS patients who are medically treated without revascularization; (5) pretreatment with DAPT (P2Y12 inhibitor) before elective or nonelective coronary angiography; (6) perioperative and longer-term APT management in patients who require coronary artery bypass grafting surgery; and (7) use of APT in patients with atrial fibrillation who require oral anticoagulation after PCI or medically managed ACS. These recommendations are all on the basis of systematic reviews and meta-analyses conducted as part of the development of these guidelines, provided in the Supplementary Material.Antiplatelet therapy (APT) is the foundation of treatment and prevention of atherothrombotic events in patients with atherosclerotic cardiovascular disease. Selecting the optimal APT strategies to reduce major adverse cardiovascular events, while balancing bleeding risk, requires ongoing review of clinical trials. Appended, the focused update of the Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology guidelines for the use of APT provides recommendations on the following topics: (1) use of acetylsalicylic acid in primary prevention of atherosclerotic cardiovascular disease; (2) dual APT (DAPT) duration after percutaneous coronary intervention (PCI) in patients at high bleeding risk; (3) potent DAPT (P2Y12 inhibitor) choice in patients who present with an acute coronary syndrome (ACS) and possible DAPT de-escalation strategies after PCI; (4) choice and duration of DAPT in ACS patients who are medically treated without revascularization; (5) pretreatment with DAPT (P2Y12 inhibitor) before elective or nonelective coronary angiography; (6) perioperative and longer-term APT management in patients who require coronary artery bypass grafting surgery; and (7) use of APT in patients with atrial fibrillation who require oral anticoagulation after PCI or medically managed ACS. These recommendations are all on the basis of systematic reviews and meta-analyses conducted as part of the development of these guidelines, provided in the Supplementary Material.
Author Fremes, Stephen E.
Liu, Shuangbo
Lordkipanidzé, Marie
Turgeon, Ricky D.
Graham, Michelle M.
Madan, Mina
Mansour, Samer
Bewick, David
Mehta, Shamir R.
Lawler, Patrick
Mancini, John
Cantor, Warren J.
Bagai, Akshay
So, Derek F.
Welsh, Robert C.
Lavoie, Andrea
Ackman, Margaret L.
Boivin-Proulx, Laurie-Anne
Potter, Brian J.
Yan, Andrew T.
Bagur, Rodrigo
Bucci, Claudia
Bainey, Kevin R.
Geller, Carol
Marquis-Gravel, Guillaume
Babadagli, Hazal E.
Shavadia, Jay
Wong, Graham C.
Tanguay, Jean-François
Belley-Côté, Emilie
Elbarouni, Basem
Author_xml – sequence: 1
  givenname: Kevin R.
  orcidid: 0000-0002-5458-4617
  surname: Bainey
  fullname: Bainey, Kevin R.
  email: kevin.bainey@albertahealthservices.ca
  organization: Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada
– sequence: 2
  givenname: Guillaume
  surname: Marquis-Gravel
  fullname: Marquis-Gravel, Guillaume
  organization: Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Québec, Canada
– sequence: 3
  givenname: Emilie
  surname: Belley-Côté
  fullname: Belley-Côté, Emilie
  organization: Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
– sequence: 4
  givenname: Ricky D.
  surname: Turgeon
  fullname: Turgeon, Ricky D.
  organization: University of British Columbia, St Paul’s Hospital PHARM-HF Clinic, Vancouver, British Columbia, Canada
– sequence: 5
  givenname: Margaret L.
  surname: Ackman
  fullname: Ackman, Margaret L.
  organization: Alberta Health Services, Edmonton, Alberta, Canada
– sequence: 6
  givenname: Hazal E.
  surname: Babadagli
  fullname: Babadagli, Hazal E.
  organization: Pharmacy Services, Alberta Health Services, Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada
– sequence: 7
  givenname: David
  surname: Bewick
  fullname: Bewick, David
  organization: Division of Cardiology, Department of Medicine, Dalhousie University, Saint John Regional Hospital, Saint John, New Brunswick, Canada
– sequence: 8
  givenname: Laurie-Anne
  surname: Boivin-Proulx
  fullname: Boivin-Proulx, Laurie-Anne
  organization: Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Québec, Canada
– sequence: 9
  givenname: Warren J.
  surname: Cantor
  fullname: Cantor, Warren J.
  organization: Southlake Regional Health Centre, University of Toronto, Toronto, Ontario, Canada
– sequence: 10
  givenname: Stephen E.
  surname: Fremes
  fullname: Fremes, Stephen E.
  organization: University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
– sequence: 11
  givenname: Michelle M.
  surname: Graham
  fullname: Graham, Michelle M.
  organization: Division of Cardiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
– sequence: 12
  givenname: Marie
  surname: Lordkipanidzé
  fullname: Lordkipanidzé, Marie
  organization: Faculté de pharmacie, Université de Montréal, Research Center, Montréal Heart Institute, Montréal, Québec, Canada
– sequence: 13
  givenname: Mina
  surname: Madan
  fullname: Madan, Mina
  organization: Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
– sequence: 14
  givenname: Samer
  surname: Mansour
  fullname: Mansour, Samer
  organization: Centre Hospitalier de l’Université de Montréal, Montréal, Québec, Canada
– sequence: 15
  givenname: Shamir R.
  surname: Mehta
  fullname: Mehta, Shamir R.
  organization: Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada
– sequence: 16
  givenname: Brian J.
  surname: Potter
  fullname: Potter, Brian J.
  organization: Centre Hospitalier de l’Université de Montréal, Montréal, Québec, Canada
– sequence: 17
  givenname: Jay
  surname: Shavadia
  fullname: Shavadia, Jay
  organization: College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
– sequence: 18
  givenname: Derek F.
  surname: So
  fullname: So, Derek F.
  organization: University of Ottawa Heart Institute, Ottawa, Ontario, Canada
– sequence: 19
  givenname: Jean-François
  surname: Tanguay
  fullname: Tanguay, Jean-François
  organization: Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Québec, Canada
– sequence: 20
  givenname: Robert C.
  surname: Welsh
  fullname: Welsh, Robert C.
  organization: Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada
– sequence: 21
  givenname: Andrew T.
  surname: Yan
  fullname: Yan, Andrew T.
  organization: Division of Cardiology, Unity Health Toronto, St Michael’s Hospital, Toronto, Ontario, Canada
– sequence: 22
  givenname: Akshay
  surname: Bagai
  fullname: Bagai, Akshay
  organization: Terrence Donnelly Heart Centre, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
– sequence: 23
  givenname: Rodrigo
  surname: Bagur
  fullname: Bagur, Rodrigo
  organization: London Health Sciences Centre, Western University, London, Ontario, Canada
– sequence: 24
  givenname: Claudia
  surname: Bucci
  fullname: Bucci, Claudia
  organization: Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
– sequence: 25
  givenname: Basem
  surname: Elbarouni
  fullname: Elbarouni, Basem
  organization: Department of Medicine, St Boniface Hospital, University of Manitoba, Winnipeg, Manitoba, Canada
– sequence: 26
  givenname: Carol
  surname: Geller
  fullname: Geller, Carol
  organization: University of Ottawa, Centretown Community Health Centre, Ottawa, Ontario, Canada
– sequence: 27
  givenname: Andrea
  surname: Lavoie
  fullname: Lavoie, Andrea
  organization: Prairie Vascular Research Inc, Regina, Saskatchewan, Canada
– sequence: 28
  givenname: Patrick
  surname: Lawler
  fullname: Lawler, Patrick
  organization: Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
– sequence: 29
  givenname: Shuangbo
  surname: Liu
  fullname: Liu, Shuangbo
  organization: Department of Medicine, St Boniface Hospital, University of Manitoba, Winnipeg, Manitoba, Canada
– sequence: 30
  givenname: John
  surname: Mancini
  fullname: Mancini, John
  organization: Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
– sequence: 31
  givenname: Graham C.
  surname: Wong
  fullname: Wong, Graham C.
  organization: Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38104631$$D View this record in MEDLINE/PubMed
BookMark eNqFkcFuGyEURVGVqnHc_kAX1Sy7GQeY8QxTdWNZTRopUheNpe4QA48GF4MLjKX5lv5sGdvpIot09cTlnie49wpdOO8AofcELwgmzfV2IbdSLCimVRYWmFSv0Ix0pClb3C4v0AwzykrK6I9LdBXjFuOatG3zBl1WjOC6qcgM_VkLJ5QRrliLoIw_iCgHK0Lx3UsDabz-d7-KMUsiGe8Kr4s7lyAcwE1nYc-09T_HYnpPcePlEEEVm70SCSYgPUJxOxgF1jiIhfbhKG3i8XaVF-1ttlpIxcMjBLEf36LXWtgI785zjjY3Xx7WX8v7b7d369V9KWvcppJ0rYQGlOoJ7ZYNk8uGLkHoGjPSSsqkalhHWgxVrXstmaa11q3Ig8i-Z6qao4-nvfvgfw8QE9-ZKMFa4cAPkdMOVxWtuvyvOfpwtg79DhTfB7MTYeRPgWYDOxlk8DEG0FyadAwtBWEsJ5hP3fEtn7rjU1aTlrvLKH2GPm1_Efp8giAHdDAQeMy9OQnKBJCJK29exj89w2Wux0hhf8H4P_gvBazH9A
CitedBy_id crossref_primary_10_1016_j_cjca_2025_01_027
crossref_primary_10_1111_hae_70047
crossref_primary_10_1177_15266028241312356
crossref_primary_10_1002_jac5_1987
crossref_primary_10_1016_j_cjco_2025_04_012
crossref_primary_10_1016_j_cjca_2025_04_005
crossref_primary_10_1002_phar_70047
crossref_primary_10_1016_j_revmed_2024_07_002
crossref_primary_10_1016_j_cjca_2023_10_027
crossref_primary_10_1016_j_cjca_2024_10_019
crossref_primary_10_1016_j_ejphar_2025_177546
crossref_primary_10_1038_s41397_025_00371_4
crossref_primary_10_1002_alz_14324
crossref_primary_10_1182_bloodadvances_2024014220
crossref_primary_10_1093_ehjacc_zuae088
crossref_primary_10_1177_17151635251339445
crossref_primary_10_1016_j_cjca_2024_09_014
Cites_doi 10.1016/j.jacc.2021.08.074
10.1016/S0140-6736(21)01063-1
10.1056/NEJMoa1817083
10.1093/eurheartj/ehu160
10.1016/S0140-6736(20)32236-4
10.1016/S0140-6736(10)61088-4
10.1016/j.jacc.2012.03.030
10.4244/EIJ-D-18-00293
10.1001/jama.2022.11966
10.1056/NEJMoa2108749
10.1056/NEJMoa0904327
10.1161/CIRCULATIONAHA.119.044598
10.1016/j.jacc.2020.03.011
10.1056/NEJMoa1904143
10.1016/j.jacc.2016.07.760
10.1016/j.jcin.2015.12.024
10.1056/NEJMoa1804988
10.1093/eurheartj/ehac284
10.1056/NEJMoa1500857
10.1016/S0140-6736(18)31924-X
10.1093/eurheartj/ehn579
10.1016/S0140-6736(20)31791-8
10.1001/jama.2022.3337
10.1056/NEJMoa0706482
10.1016/j.ejcts.2009.05.032
10.1016/j.ahj.2022.05.017
10.1093/eurheartj/ehz821
10.1136/bmj.d3527
10.1016/j.jacc.2010.10.029
10.1016/j.jcin.2023.01.366
10.1016/S0140-6736(01)05701-4
10.1016/j.jacc.2018.11.048
10.1016/j.cjca.2018.11.031
10.1016/j.jacc.2010.01.067
10.1161/CIRCULATIONAHA.120.046534
10.1056/NEJMoa1908973
10.1161/CIRCULATIONAHA.123.065448
10.1016/j.jacc.2020.05.031
10.1016/S0140-6736(19)31872-0
10.1161/CIRCINTERVENTIONS.121.010849
10.1161/CIRCULATIONAHA.109.912550
10.1016/S0140-6736(13)61615-3
10.1001/jamacardio.2019.1880
10.1016/S0140-6736(13)61840-1
10.1136/heartjnl-2020-318694
10.1056/NEJMoa1407024
10.1161/CIRCULATIONAHA.118.036768
10.1016/j.ijcard.2019.04.043
10.1161/01.CIR.0000161383.06692.D4
10.1016/j.jacc.2017.11.008
10.1056/NEJMoa1709118
10.1016/j.cjco.2023.08.011
10.1056/NEJMoa1800722
10.1093/eurheartj/ehv381
10.1016/j.cjca.2013.07.001
10.1016/S0140-6736(21)01445-8
10.1161/CIRCINTERVENTIONS.119.008649
10.1056/EVIDoa2100047
10.1016/j.cjca.2017.12.012
10.1001/jamacardio.2016.3028
10.1016/j.cjca.2020.09.001
10.1056/NEJMoa1910021
10.1093/eurheartj/ehx175
10.1056/NEJMoa1308075
10.1016/j.jacc.2023.04.051
10.1161/CIRCULATIONAHA.116.024823
10.1007/s00392-011-0393-1
10.1161/CIRCULATIONAHA.123.064473
10.1016/j.jacc.2020.08.053
10.1161/CIRCULATIONAHA.119.040167
10.1371/journal.pone.0291061
10.1016/j.cjca.2010.12.015
10.1016/j.cjca.2012.06.012
10.1056/NEJMoa1409312
10.1093/icvts/ivaa115
10.1016/S0140-6736(96)09457-3
10.1016/j.jacadv.2022.100197
10.1136/bmj.l5476
10.1056/NEJMoa2028220
10.1016/j.jacc.2009.06.021
10.1161/01.CIR.0000051362.96946.15
10.1056/NEJMoa1205512
ContentType Journal Article
Copyright 2023 Canadian Cardiovascular Society
Copyright © 2023 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2023 Canadian Cardiovascular Society
– notice: Copyright © 2023 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
CorporateAuthor Primary Panel
Secondary Panel
CorporateAuthor_xml – name: Secondary Panel
– name: Primary Panel
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.cjca.2023.10.013
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1916-7075
EndPage 181
ExternalDocumentID 38104631
10_1016_j_cjca_2023_10_013
S0828282X2301841X
Genre Practice Guideline
GeographicLocations Canada
GeographicLocations_xml – name: Canada
GroupedDBID ---
--K
--M
.1-
.FO
.GJ
.~1
0R~
1P~
1~.
1~5
29B
4.4
457
4G.
53G
5GY
5RE
5VS
6J9
7-5
8P~
AAEDT
AAEDW
AAFWJ
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABJNI
ABLJU
ABMAC
ABMZM
ABWVN
ABXDB
ACDAQ
ACGFO
ACIEU
ACJTP
ACLOT
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADVLN
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXBA
AFXIZ
AGHFR
AGUBO
AGYEJ
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
AXJTR
BKOJK
BLXMC
BNPGV
E3Z
EBS
EFJIC
EFKBS
EFLBG
EJD
F5P
FDB
FEDTE
FIRID
FNPLU
FYGXN
GBLVA
HVGLF
HX~
HYE
HZ~
J1W
KOM
M41
MO0
O-L
O9-
OAUVE
OA~
OK1
OL0
P-8
P-9
P2P
PC.
Q38
ROL
RPM
SDF
SEL
SES
SJN
SNG
SPCBC
SSH
SSZ
T5K
TR2
Z5R
~G-
~HD
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
AAYXX
CITATION
AGCQF
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c407t-197ce6eddb129568c5625eaf40817c28cd689170e34fbfc8f24ff7af241cbb8d3
ISICitedReferencesCount 27
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001187960200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0828-282X
1916-7075
IngestDate Sun Nov 09 10:41:51 EST 2025
Tue Apr 29 09:22:40 EDT 2025
Tue Nov 18 22:42:19 EST 2025
Sat Nov 29 05:54:05 EST 2025
Sat Sep 07 15:51:17 EDT 2024
Tue Oct 14 19:31:36 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License Copyright © 2023 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c407t-197ce6eddb129568c5625eaf40817c28cd689170e34fbfc8f24ff7af241cbb8d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Instructional Material/Guideline-2
ObjectType-Feature-3
content type line 23
ORCID 0000-0002-5458-4617
PMID 38104631
PQID 2903323902
PQPubID 23479
PageCount 22
ParticipantIDs proquest_miscellaneous_2903323902
pubmed_primary_38104631
crossref_citationtrail_10_1016_j_cjca_2023_10_013
crossref_primary_10_1016_j_cjca_2023_10_013
elsevier_sciencedirect_doi_10_1016_j_cjca_2023_10_013
elsevier_clinicalkey_doi_10_1016_j_cjca_2023_10_013
PublicationCentury 2000
PublicationDate February 2024
2024-02-00
20240201
PublicationDateYYYYMMDD 2024-02-01
PublicationDate_xml – month: 02
  year: 2024
  text: February 2024
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Canadian journal of cardiology
PublicationTitleAlternate Can J Cardiol
PublicationYear 2024
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Costa, Van Klaveren, Feres (bib15) 2019; 73
Marquis-Gravel, Dalgaard, Jones (bib11) 2020; 76
Koo, Kang, Park (bib25) 2021; 397
Firanescu, Martens, Schönberger, Soliman Hamad, van Straten (bib64) 2009; 36
Wiviott, Braunwald, McCabe (bib32) 2007; 357
Montalescot, Bolognese, Dudek (bib50) 2013; 369
Montalescot, van 't Hof, Lapostolle (bib46) 2014; 371
Landi, Heg, Frigoli (bib22) 2023; 16
Yusuf, Joseph, Dans (bib7) 2021; 384
Gragnano, Cao, Pirondini (bib27) 2023; 82
Schmitt, Duray, Gersh, Hohnloser (bib74) 2009; 30
Andrade, Aguilar, Atzema (bib81) 2020; 36
Montalescot, van 't Hof, Bolognese (bib47) 2016; 9
Bonaca, Bhatt, Cohen (bib30) 2015; 372
Venetsanos, Träff, Erlinge (bib35) 2021; 107
Andrade, Deyell, Khoo, Lee, Humphries, Cairns (bib73) 2013; 29
Bowman, Mafham (bib5) 2018; 379
Alexander, Wojdyla, Vora (bib78) 2020; 141
Kim, Kang, Hwang (bib41) 2020; 396
Solo, Lavi, Kabali (bib70) 2019; 367
Gent (bib26) 1996; 348
Guirguis-Blake, Evans, Perdue, Bean, Senger (bib9) 2022; 327
Tanguay, Bell, Ackman (bib2) 2013; 29
Mauri, Kereiakes, Yeh (bib29) 2014; 371
Dangas, Mehran, Guagliumi (bib59) 2009; 54
McNeil, Woods, Nelson (bib4) 2018; 379
Furtado, Nicolau, Magnani (bib45) 2020; 41
James, Roe, Cannon (bib43) 2011; 342
Zeymer, Arntz, Mark (bib48) 2012; 101
Bainey, Welsh, Connolly (bib83) 2020; 141
Windecker, Latib, Kedhi (bib12) 2020; 382
Valgimigli, Frigoli, Heg (bib21) 2021; 385
Motovska, Hlinomaz, Miklik (bib36) 2016; 134
Valgimigli, Cao, Angiolillo (bib13) 2021; 78
Lindholm, Varenhorst, Cannon (bib44) 2014; 235
Held, Asenblad, Bassand (bib61) 2011; 57
Valgimigli, Smits, Frigoli (bib20) 2022; 43
Vranckx, Valgimigli, Eckardt (bib77) 2019; 394
Steg, Bhatt, Hamm (bib84) 2013; 382
Urban, Mehran, Colleran (bib14) 2019; 140
Gurbel, Bliden, Butler (bib63) 2009; 120
Cuisset, Deharo, Quilici (bib39) 2017; 38
So, Wells, Lordkipanidze (bib65)
Azzalini, Poletti, Lombardo (bib18) 2019; 290
Sandner, Redfors, Angiolillo (bib71) 2022; 328
Hansson, Jidéus, Åberg (bib66) 2016; 37
Tarantini, Mojoli, Varbella (bib51) 2020; 76
Gherli, Mariscalco, Dalén (bib67) 2016; 1
Smith, Goodnough, Levy (bib72) 2012; 60
Gupta, Belley-Cote, Panchal (bib69) 2020; 31
Lipiecki, Brunel, Morice (bib17) 2018; 14
Roe, Armstrong, Fox (bib42) 2012; 367
Motovska, Hlinomaz, Kala (bib37) 2018; 71
Laferriere, Moazzami, Belley-Cote (bib8) 2023; 5
Lopes, Heizer, Aronson (bib76) 2019; 380
Capodanno, Mehran, Krucoff (bib28) 2023; 147
Mehta, Tanguay, Eikelboom (bib60) 2010; 376
Wallentin, Becker, Budaj (bib33) 2009; 361
Mehta, Bainey, Cantor (bib3) 2018; 34
Jurga, Szummer, Lewinter (bib55) 2021; 14
Silvain, Lattuca, Beygui (bib56) 2020; 396
Natsuaki, Watanabe, Morimoto (bib23) 2023
Mehta, Yusuf, Peters (bib52) 2001; 358
Bainey, Marquis-Gravel, MacDonald, Bewick, Yan, Turgeon (bib24) 2023; 18
Valgimigli, Wlodarczak, Tölg (bib31) 2023; 148
Patti, Colonna, Pasceri, Pepe, Montinaro, Di Sciascio (bib58) 2005; 111
Dangas, Baber, Sharma (bib19) 2020; 75
Khan, Lone, Kleiman (bib10) 2023; 2
Mehilli, Baquet, Hochholzer (bib57) 2020; 13
Schüpke, Neumann, Menichelli (bib34) 2019; 381
Mehta (bib85) 2013; 382
Matsumura-Nakano, Shizuta, Komasa (bib79) 2019; 139
Di Sciascio, Patti, Pasceri (bib54) 2010; 56
Bhatt, Pollack, Mazer (bib68) 2022; 1
Lopes, Hong, Harskamp (bib75) 2019; 4
Giustino, Chieffo, Palmerini (bib16) 2016; 68
Wong, Welsford, Ainsworth (bib49) 2019; 35
Yusuf, Mehta, Zhao (bib53) 2003; 107
Omerovic, Erlinge, Koul (bib38) 2022; 251
Yasuda, Kaikita, Akao (bib80) 2019; 381
Eikelboom, Connolly, Bosch (bib82) 2017; 377
Gaziano, Brotons, Coppolecchia (bib6) 2018; 392
Sarathy, Wells, Singh (bib62) 2021; 10
Bell, Roussin, Cartier (bib1) 2011; 27
Kim, Park, Kim (bib40) 2021; 398
Mehta (10.1016/j.cjca.2023.10.013_bib60) 2010; 376
Bonaca (10.1016/j.cjca.2023.10.013_bib30) 2015; 372
Gupta (10.1016/j.cjca.2023.10.013_bib69) 2020; 31
Gent (10.1016/j.cjca.2023.10.013_bib26) 1996; 348
Mehilli (10.1016/j.cjca.2023.10.013_bib57) 2020; 13
Laferriere (10.1016/j.cjca.2023.10.013_bib8) 2023; 5
Motovska (10.1016/j.cjca.2023.10.013_bib37) 2018; 71
Natsuaki (10.1016/j.cjca.2023.10.013_bib23) 2023
Zeymer (10.1016/j.cjca.2023.10.013_bib48) 2012; 101
Capodanno (10.1016/j.cjca.2023.10.013_bib28) 2023; 147
Wiviott (10.1016/j.cjca.2023.10.013_bib32) 2007; 357
Schüpke (10.1016/j.cjca.2023.10.013_bib34) 2019; 381
Yusuf (10.1016/j.cjca.2023.10.013_bib53) 2003; 107
Held (10.1016/j.cjca.2023.10.013_bib61) 2011; 57
Valgimigli (10.1016/j.cjca.2023.10.013_bib20) 2022; 43
Bell (10.1016/j.cjca.2023.10.013_bib1) 2011; 27
Kim (10.1016/j.cjca.2023.10.013_bib41) 2020; 396
Firanescu (10.1016/j.cjca.2023.10.013_bib64) 2009; 36
Kim (10.1016/j.cjca.2023.10.013_bib40) 2021; 398
Yusuf (10.1016/j.cjca.2023.10.013_bib7) 2021; 384
Silvain (10.1016/j.cjca.2023.10.013_bib56) 2020; 396
Sarathy (10.1016/j.cjca.2023.10.013_bib62) 2021; 10
Lopes (10.1016/j.cjca.2023.10.013_bib76) 2019; 380
Sandner (10.1016/j.cjca.2023.10.013_bib71) 2022; 328
James (10.1016/j.cjca.2023.10.013_bib43) 2011; 342
Lindholm (10.1016/j.cjca.2023.10.013_bib44) 2014; 235
Mauri (10.1016/j.cjca.2023.10.013_bib29) 2014; 371
Montalescot (10.1016/j.cjca.2023.10.013_bib47) 2016; 9
Guirguis-Blake (10.1016/j.cjca.2023.10.013_bib9) 2022; 327
Gragnano (10.1016/j.cjca.2023.10.013_bib27) 2023; 82
Di Sciascio (10.1016/j.cjca.2023.10.013_bib54) 2010; 56
Mehta (10.1016/j.cjca.2023.10.013_bib52) 2001; 358
Dangas (10.1016/j.cjca.2023.10.013_bib19) 2020; 75
Jurga (10.1016/j.cjca.2023.10.013_bib55) 2021; 14
Windecker (10.1016/j.cjca.2023.10.013_bib12) 2020; 382
Wallentin (10.1016/j.cjca.2023.10.013_bib33) 2009; 361
Bainey (10.1016/j.cjca.2023.10.013_bib83) 2020; 141
Patti (10.1016/j.cjca.2023.10.013_bib58) 2005; 111
Lopes (10.1016/j.cjca.2023.10.013_bib75) 2019; 4
Matsumura-Nakano (10.1016/j.cjca.2023.10.013_bib79) 2019; 139
Venetsanos (10.1016/j.cjca.2023.10.013_bib35) 2021; 107
Gaziano (10.1016/j.cjca.2023.10.013_bib6) 2018; 392
Lipiecki (10.1016/j.cjca.2023.10.013_bib17) 2018; 14
Bhatt (10.1016/j.cjca.2023.10.013_bib68) 2022; 1
Alexander (10.1016/j.cjca.2023.10.013_bib78) 2020; 141
Valgimigli (10.1016/j.cjca.2023.10.013_bib13) 2021; 78
Andrade (10.1016/j.cjca.2023.10.013_bib81) 2020; 36
Valgimigli (10.1016/j.cjca.2023.10.013_bib21) 2021; 385
Montalescot (10.1016/j.cjca.2023.10.013_bib46) 2014; 371
Azzalini (10.1016/j.cjca.2023.10.013_bib18) 2019; 290
Furtado (10.1016/j.cjca.2023.10.013_bib45) 2020; 41
Montalescot (10.1016/j.cjca.2023.10.013_bib50) 2013; 369
Cuisset (10.1016/j.cjca.2023.10.013_bib39) 2017; 38
Motovska (10.1016/j.cjca.2023.10.013_bib36) 2016; 134
Roe (10.1016/j.cjca.2023.10.013_bib42) 2012; 367
Eikelboom (10.1016/j.cjca.2023.10.013_bib82) 2017; 377
Mehta (10.1016/j.cjca.2023.10.013_bib85) 2013; 382
Smith (10.1016/j.cjca.2023.10.013_bib72) 2012; 60
Khan (10.1016/j.cjca.2023.10.013_bib10) 2023; 2
Omerovic (10.1016/j.cjca.2023.10.013_bib38) 2022; 251
Yasuda (10.1016/j.cjca.2023.10.013_bib80) 2019; 381
Bainey (10.1016/j.cjca.2023.10.013_bib24) 2023; 18
So (10.1016/j.cjca.2023.10.013_bib65)
Mehta (10.1016/j.cjca.2023.10.013_bib3) 2018; 34
Tarantini (10.1016/j.cjca.2023.10.013_bib51) 2020; 76
Dangas (10.1016/j.cjca.2023.10.013_bib59) 2009; 54
Andrade (10.1016/j.cjca.2023.10.013_bib73) 2013; 29
Marquis-Gravel (10.1016/j.cjca.2023.10.013_bib11) 2020; 76
Schmitt (10.1016/j.cjca.2023.10.013_bib74) 2009; 30
Vranckx (10.1016/j.cjca.2023.10.013_bib77) 2019; 394
Landi (10.1016/j.cjca.2023.10.013_bib22) 2023; 16
Solo (10.1016/j.cjca.2023.10.013_bib70) 2019; 367
Gurbel (10.1016/j.cjca.2023.10.013_bib63) 2009; 120
Bowman (10.1016/j.cjca.2023.10.013_bib5) 2018; 379
McNeil (10.1016/j.cjca.2023.10.013_bib4) 2018; 379
Valgimigli (10.1016/j.cjca.2023.10.013_bib31) 2023; 148
Giustino (10.1016/j.cjca.2023.10.013_bib16) 2016; 68
Wong (10.1016/j.cjca.2023.10.013_bib49) 2019; 35
Steg (10.1016/j.cjca.2023.10.013_bib84) 2013; 382
Hansson (10.1016/j.cjca.2023.10.013_bib66) 2016; 37
Gherli (10.1016/j.cjca.2023.10.013_bib67) 2016; 1
Tanguay (10.1016/j.cjca.2023.10.013_bib2) 2013; 29
Urban (10.1016/j.cjca.2023.10.013_bib14) 2019; 140
Koo (10.1016/j.cjca.2023.10.013_bib25) 2021; 397
Costa (10.1016/j.cjca.2023.10.013_bib15) 2019; 73
38740360 - Can J Cardiol. 2024 May 10
References_xml – volume: 380
  start-page: 1509
  year: 2019
  end-page: 1524
  ident: bib76
  article-title: Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation
  publication-title: N Engl J Med
– volume: 377
  start-page: 1319
  year: 2017
  end-page: 1330
  ident: bib82
  article-title: Rivaroxaban with or without aspirin in stable cardiovascular disease
  publication-title: N Engl J Med
– volume: 73
  start-page: 741
  year: 2019
  end-page: 754
  ident: bib15
  article-title: Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting
  publication-title: J Am Coll Cardiol
– volume: 141
  start-page: 1141
  year: 2020
  end-page: 1151
  ident: bib83
  article-title: Rivaroxaban plus aspirin versus aspirin alone in patients with prior percutaneous coronary intervention (COMPASS-PCI)
  publication-title: Circulation
– volume: 348
  start-page: 1329
  year: 1996
  end-page: 1339
  ident: bib26
  article-title: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee
  publication-title: Lancet
– volume: 371
  start-page: 2155
  year: 2014
  end-page: 2166
  ident: bib29
  article-title: Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
  publication-title: N Engl J Med
– volume: 357
  start-page: 2001
  year: 2007
  end-page: 2015
  ident: bib32
  article-title: Prasugrel versus clopidogrel in patients with acute coronary syndromes
  publication-title: N Engl J Med
– volume: 392
  start-page: 1036
  year: 2018
  end-page: 1046
  ident: bib6
  article-title: Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
  publication-title: Lancet
– volume: 379
  start-page: 1529
  year: 2018
  end-page: 1539
  ident: bib5
  article-title: Effects of aspirin for primary prevention in persons with diabetes mellitus
  publication-title: N Engl J Med
– volume: 35
  start-page: 107
  year: 2019
  end-page: 132
  ident: bib49
  article-title: 2019 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Guidelines on the acute management of ST-elevation myocardial infarction: focused update on regionalization and reperfusion
  publication-title: Can J Cardiol
– volume: 384
  start-page: 216
  year: 2021
  end-page: 228
  ident: bib7
  article-title: Polypill with or without aspirin in persons without cardiovascular disease
  publication-title: N Engl J Med
– volume: 327
  start-page: 1585
  year: 2022
  end-page: 1597
  ident: bib9
  article-title: Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US preventive services task force
  publication-title: JAMA
– volume: 75
  start-page: 2414
  year: 2020
  end-page: 2424
  ident: bib19
  article-title: Ticagrelor with or without aspirin after complex PCI
  publication-title: J Am Coll Cardiol
– volume: 394
  start-page: 1335
  year: 2019
  end-page: 1343
  ident: bib77
  article-title: Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
  publication-title: Lancet
– volume: 18
  year: 2023
  ident: bib24
  article-title: Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: systematic review and meta-analysis
  publication-title: PLoS One
– year: 2023
  ident: bib23
  article-title: An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial [epub ahead of press]
  publication-title: Circulation
– volume: 367
  start-page: l5476
  year: 2019
  ident: bib70
  article-title: Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis
  publication-title: BMJ
– volume: 382
  start-page: 1960
  year: 2013
  end-page: 1962
  ident: bib85
  article-title: Cangrelor: a new CHAMPION for percutaneous coronary intervention
  publication-title: Lancet
– volume: 4
  start-page: 747
  year: 2019
  end-page: 755
  ident: bib75
  article-title: Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials
  publication-title: JAMA Cardiol
– volume: 78
  start-page: 2060
  year: 2021
  end-page: 2072
  ident: bib13
  article-title: Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI
  publication-title: J Am Coll Cardiol
– volume: 111
  start-page: 2099
  year: 2005
  end-page: 2106
  ident: bib58
  article-title: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study
  publication-title: Circulation
– volume: 361
  start-page: 1045
  year: 2009
  end-page: 1057
  ident: bib33
  article-title: Ticagrelor versus clopidogrel in patients with acute coronary syndromes
  publication-title: N Engl J Med
– volume: 36
  start-page: 1847
  year: 2020
  end-page: 1848
  ident: bib81
  article-title: The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation
  publication-title: Can J Cardiol
– volume: 369
  start-page: 999
  year: 2013
  end-page: 1010
  ident: bib50
  article-title: Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes
  publication-title: N Engl J Med
– volume: 27
  start-page: S1
  year: 2011
  end-page: S59
  ident: bib1
  article-title: The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines
  publication-title: Can J Cardiol
– volume: 16
  start-page: 798
  year: 2023
  end-page: 812
  ident: bib22
  article-title: Abbreviated or standard antiplatelet therapy in HBR patients: final 15-month results of the MASTER-DAPT trial
  publication-title: JACC Cardiovasc Interv
– volume: 1
  start-page: 921
  year: 2016
  end-page: 928
  ident: bib67
  article-title: Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting
  publication-title: JAMA Cardiol
– volume: 358
  start-page: 527
  year: 2001
  end-page: 533
  ident: bib52
  article-title: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
  publication-title: Lancet
– volume: 37
  start-page: 189
  year: 2016
  end-page: 197
  ident: bib66
  article-title: Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study
  publication-title: Eur Heart J
– volume: 60
  start-page: 388
  year: 2012
  end-page: 396
  ident: bib72
  article-title: Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis
  publication-title: J Am Coll Cardiol
– volume: 31
  start-page: 354
  year: 2020
  end-page: 363
  ident: bib69
  article-title: Antiplatelet therapy and coronary artery bypass grafting: a systematic review and network meta-analysis
  publication-title: Interact Cardiovasc Thorac Surg
– volume: 13
  year: 2020
  ident: bib57
  article-title: Randomized comparison of intensified and standard P2Y12-receptor-inhibition before elective percutaneous coronary intervention: the SASSICAIA trial
  publication-title: Circ Cardiovasc Interv
– volume: 148
  start-page: 989
  year: 2023
  end-page: 999
  ident: bib31
  article-title: Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: a randomized, open-label clinical trial
  publication-title: Circulation
– volume: 57
  start-page: 672
  year: 2011
  end-page: 684
  ident: bib61
  article-title: Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial
  publication-title: J Am Coll Cardiol
– volume: 2
  year: 2023
  ident: bib10
  article-title: Aspirin with or without statin in individuals without atherosclerotic cardiovascular disease across risk categories
  publication-title: JACC Adv
– volume: 29
  start-page: 204
  year: 2013
  end-page: 212
  ident: bib73
  article-title: Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention/stenting: a systematic review and meta-analysis
  publication-title: Can J Cardiol
– volume: 147
  start-page: 1933
  year: 2023
  end-page: 1944
  ident: bib28
  article-title: Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the Academic Research Consortium
  publication-title: Circulation
– volume: 101
  start-page: 305
  year: 2012
  end-page: 312
  ident: bib48
  article-title: Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial
  publication-title: Clin Res Cardiol
– volume: 396
  start-page: 1079
  year: 2020
  end-page: 1089
  ident: bib41
  article-title: Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial
  publication-title: Lancet
– volume: 385
  start-page: 1643
  year: 2021
  end-page: 1655
  ident: bib21
  article-title: Dual antiplatelet therapy after PCI in patients at high bleeding risk
  publication-title: N Engl J Med
– volume: 251
  start-page: 70
  year: 2022
  end-page: 77
  ident: bib38
  article-title: Rationale and design of switch Swedeheart: a registry-based, stepped-wedge, cluster-randomized, open-label multicenter trial to compare prasugrel and ticagrelor for treatment of patients with acute coronary syndrome
  publication-title: Am Heart J
– volume: 120
  start-page: 2577
  year: 2009
  end-page: 2585
  ident: bib63
  article-title: Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study
  publication-title: Circulation
– volume: 10
  start-page: 1
  year: 2021
  end-page: 4
  ident: bib62
  article-title: Platelet quiescence in patients with acute coronary syndrome undergoing coronary artery bypass graft surgery
  publication-title: J Am Heart Assoc
– volume: 381
  start-page: 1524
  year: 2019
  end-page: 1534
  ident: bib34
  article-title: Ticagrelor or prasugrel in patients with acute coronary syndromes
  publication-title: N Engl J Med
– volume: 71
  start-page: 371
  year: 2018
  end-page: 381
  ident: bib37
  article-title: 1-Year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor
  publication-title: J Am Coll Cardiol
– volume: 14
  year: 2021
  ident: bib55
  article-title: Pretreatment with P2Y12 inhibitors in patients with chronic coronary syndrome undergoing percutaneous coronary intervention: a report from the Swedish Coronary Angiography and Angioplasty Registry
  publication-title: Circ Cardiovasc Interv
– volume: 381
  start-page: 1103
  year: 2019
  end-page: 1113
  ident: bib80
  article-title: Antithrombotic therapy for atrial fibrillation with stable coronary disease
  publication-title: N Engl J Med
– volume: 107
  start-page: 966
  year: 2003
  end-page: 972
  ident: bib53
  article-title: Early and late effects of clopidogrel in patients with acute coronary syndromes
  publication-title: Circulation
– volume: 382
  start-page: 1981
  year: 2013
  end-page: 1992
  ident: bib84
  article-title: Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data
  publication-title: Lancet
– volume: 371
  start-page: 1016
  year: 2014
  end-page: 1027
  ident: bib46
  article-title: Prehospital ticagrelor in ST-segment elevation myocardial infarction
  publication-title: N Engl J Med
– volume: 290
  start-page: 59
  year: 2019
  end-page: 63
  ident: bib18
  article-title: Risk of contrast-induced nephropathy in patients undergoing complex percutaneous coronary intervention
  publication-title: Int J Cardiol
– volume: 141
  start-page: 1618
  year: 2020
  end-page: 1627
  ident: bib78
  article-title: Risk/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS
  publication-title: Circulation
– volume: 14
  start-page: e418
  year: 2018
  end-page: e425
  ident: bib17
  article-title: Biolimus A9 polymer-free coated stents in high bleeding risk patients undergoing complex PCI, evidence from the LEADERS FREE randomised clinical trial
  publication-title: EuroIntervention
– volume: 1
  year: 2022
  ident: bib68
  article-title: Bentracimab for ticagrelor reversal in patients undergoing urgent surgery
  publication-title: NEJM Evid
– volume: 367
  start-page: 1297
  year: 2012
  end-page: 1309
  ident: bib42
  article-title: Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
  publication-title: N Engl J Med
– volume: 29
  start-page: 1334
  year: 2013
  end-page: 1345
  ident: bib2
  article-title: Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy
  publication-title: Can J Cardiol
– volume: 82
  start-page: 89
  year: 2023
  end-page: 105
  ident: bib27
  article-title: P2Y
  publication-title: J Am Coll Cardiol
– volume: 5
  start-page: 881
  year: 2023
  end-page: 890
  ident: bib8
  article-title: Aspirin for the primary prevention of vascular ischemic events: an updated systematic review and meta-analysis to support shared decision-making
  publication-title: CJC Open
– volume: 140
  start-page: 240
  year: 2019
  end-page: 261
  ident: bib14
  article-title: Defining high bleeding risk in patients undergoing percutaneous coronary intervention
  publication-title: Circulation
– volume: 54
  start-page: 1438
  year: 2009
  end-page: 1446
  ident: bib59
  article-title: Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial
  publication-title: J Am Coll Cardiol
– volume: 56
  start-page: 550
  year: 2010
  end-page: 557
  ident: bib54
  article-title: Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial
  publication-title: J Am Coll Cardiol
– volume: 379
  start-page: 1499
  year: 2018
  end-page: 1508
  ident: bib4
  article-title: Effect of aspirin on disability-free survival in the healthy elderly
  publication-title: N Engl J Med
– volume: 398
  start-page: 1305
  year: 2021
  end-page: 1316
  ident: bib40
  article-title: Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial
  publication-title: Lancet
– volume: 41
  start-page: 1625
  year: 2020
  end-page: 1632
  ident: bib45
  article-title: Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
  publication-title: Eur Heart J
– volume: 43
  start-page: 3100
  year: 2022
  end-page: 3114
  ident: bib20
  article-title: Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis
  publication-title: Eur Heart J
– volume: 397
  start-page: 2487
  year: 2021
  end-page: 2496
  ident: bib25
  article-title: Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial
  publication-title: Lancet
– volume: 134
  start-page: 1603
  year: 2016
  end-page: 1612
  ident: bib36
  article-title: Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study
  publication-title: Circulation
– volume: 396
  start-page: 1737
  year: 2020
  end-page: 1744
  ident: bib56
  article-title: Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial
  publication-title: Lancet
– volume: 328
  start-page: 554
  year: 2022
  end-page: 562
  ident: bib71
  article-title: Association of dual antiplatelet therapy with ticagrelor with vein graft failure after coronary artery bypass graft surgery: a systematic review and meta-analysis
  publication-title: JAMA
– volume: 372
  start-page: 1791
  year: 2015
  end-page: 1800
  ident: bib30
  article-title: Long-term use of ticagrelor in patients with prior myocardial infarction
  publication-title: N Engl J Med
– volume: 9
  start-page: 646
  year: 2016
  end-page: 656
  ident: bib47
  article-title: Effect of pre-hospital ticagrelor during the first 24 h after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: the ATLANTIC-H
  publication-title: JACC Cardiovasc Interv
– volume: 76
  start-page: 2450
  year: 2020
  end-page: 2459
  ident: bib51
  article-title: Timing of oral P2Y12 inhibitor administration in patients with non-ST-segment elevation acute coronary syndrome
  publication-title: J Am Coll Cardiol
– volume: 376
  start-page: 1233
  year: 2010
  end-page: 1243
  ident: bib60
  article-title: Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
  publication-title: Lancet
– volume: 382
  start-page: 1208
  year: 2020
  end-page: 1218
  ident: bib12
  article-title: Polymer-based or polymer-free stents in patients at high bleeding risk
  publication-title: N Engl J Med
– volume: 30
  start-page: 1038
  year: 2009
  end-page: 1045
  ident: bib74
  article-title: Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications
  publication-title: Eur Heart J
– volume: 76
  start-page: 162
  year: 2020
  end-page: 171
  ident: bib11
  article-title: Post-discharge bleeding and mortality following acute coronary syndromes with or without PCI
  publication-title: J Am Coll Cardiol
– volume: 107
  start-page: 1145
  year: 2021
  end-page: 1151
  ident: bib35
  article-title: Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention
  publication-title: Heart
– volume: 235
  start-page: 2083
  year: 2014
  end-page: 2093
  ident: bib44
  article-title: Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial
  publication-title: Eur Heart J
– volume: 139
  start-page: 604
  year: 2019
  end-page: 616
  ident: bib79
  article-title: Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation
  publication-title: Circulation
– volume: 68
  start-page: 1851
  year: 2016
  end-page: 1864
  ident: bib16
  article-title: Efficacy and safety of dual antiplatelet therapy after complex PCI
  publication-title: J Am Coll Cardiol
– volume: 38
  start-page: 3070
  year: 2017
  end-page: 3078
  ident: bib39
  article-title: Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study
  publication-title: Eur Heart J
– volume: 34
  start-page: 214
  year: 2018
  end-page: 233
  ident: bib3
  article-title: 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy
  publication-title: Can J Cardiol
– volume: 36
  start-page: 856
  year: 2009
  end-page: 862
  ident: bib64
  article-title: Postoperative blood loss in patients undergoing coronary artery bypass surgery after preoperative treatment with clopidogrel. A prospective randomised controlled study
  publication-title: Eur J Cardiothorac Surg
– ident: bib65
  article-title: A randomized study of early vs. delayed coronary artery bypass surgery among patients with acute coronary syndromes treated with ticagrelor: the RAPID CABG study
– volume: 342
  start-page: d3527
  year: 2011
  ident: bib43
  article-title: Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial
  publication-title: BMJ
– volume: 78
  start-page: 2060
  year: 2021
  ident: 10.1016/j.cjca.2023.10.013_bib13
  article-title: Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2021.08.074
– volume: 397
  start-page: 2487
  issue: 10293
  year: 2021
  ident: 10.1016/j.cjca.2023.10.013_bib25
  article-title: Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)01063-1
– volume: 380
  start-page: 1509
  year: 2019
  ident: 10.1016/j.cjca.2023.10.013_bib76
  article-title: Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1817083
– volume: 235
  start-page: 2083
  year: 2014
  ident: 10.1016/j.cjca.2023.10.013_bib44
  article-title: Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehu160
– volume: 396
  start-page: 1737
  year: 2020
  ident: 10.1016/j.cjca.2023.10.013_bib56
  article-title: Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)32236-4
– volume: 376
  start-page: 1233
  year: 2010
  ident: 10.1016/j.cjca.2023.10.013_bib60
  article-title: Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)61088-4
– volume: 60
  start-page: 388
  year: 2012
  ident: 10.1016/j.cjca.2023.10.013_bib72
  article-title: Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2012.03.030
– volume: 14
  start-page: e418
  year: 2018
  ident: 10.1016/j.cjca.2023.10.013_bib17
  article-title: Biolimus A9 polymer-free coated stents in high bleeding risk patients undergoing complex PCI, evidence from the LEADERS FREE randomised clinical trial
  publication-title: EuroIntervention
  doi: 10.4244/EIJ-D-18-00293
– volume: 328
  start-page: 554
  year: 2022
  ident: 10.1016/j.cjca.2023.10.013_bib71
  article-title: Association of dual antiplatelet therapy with ticagrelor with vein graft failure after coronary artery bypass graft surgery: a systematic review and meta-analysis
  publication-title: JAMA
  doi: 10.1001/jama.2022.11966
– volume: 385
  start-page: 1643
  year: 2021
  ident: 10.1016/j.cjca.2023.10.013_bib21
  article-title: Dual antiplatelet therapy after PCI in patients at high bleeding risk
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2108749
– volume: 361
  start-page: 1045
  year: 2009
  ident: 10.1016/j.cjca.2023.10.013_bib33
  article-title: Ticagrelor versus clopidogrel in patients with acute coronary syndromes
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0904327
– volume: 141
  start-page: 1141
  year: 2020
  ident: 10.1016/j.cjca.2023.10.013_bib83
  article-title: Rivaroxaban plus aspirin versus aspirin alone in patients with prior percutaneous coronary intervention (COMPASS-PCI)
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.119.044598
– volume: 75
  start-page: 2414
  year: 2020
  ident: 10.1016/j.cjca.2023.10.013_bib19
  article-title: Ticagrelor with or without aspirin after complex PCI
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2020.03.011
– volume: 381
  start-page: 1103
  year: 2019
  ident: 10.1016/j.cjca.2023.10.013_bib80
  article-title: Antithrombotic therapy for atrial fibrillation with stable coronary disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1904143
– volume: 68
  start-page: 1851
  year: 2016
  ident: 10.1016/j.cjca.2023.10.013_bib16
  article-title: Efficacy and safety of dual antiplatelet therapy after complex PCI
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2016.07.760
– volume: 9
  start-page: 646
  year: 2016
  ident: 10.1016/j.cjca.2023.10.013_bib47
  article-title: Effect of pre-hospital ticagrelor during the first 24 h after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: the ATLANTIC-H24 analysis
  publication-title: JACC Cardiovasc Interv
  doi: 10.1016/j.jcin.2015.12.024
– volume: 379
  start-page: 1529
  year: 2018
  ident: 10.1016/j.cjca.2023.10.013_bib5
  article-title: Effects of aspirin for primary prevention in persons with diabetes mellitus
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1804988
– volume: 43
  start-page: 3100
  year: 2022
  ident: 10.1016/j.cjca.2023.10.013_bib20
  article-title: Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehac284
– volume: 372
  start-page: 1791
  year: 2015
  ident: 10.1016/j.cjca.2023.10.013_bib30
  article-title: Long-term use of ticagrelor in patients with prior myocardial infarction
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1500857
– volume: 392
  start-page: 1036
  year: 2018
  ident: 10.1016/j.cjca.2023.10.013_bib6
  article-title: Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(18)31924-X
– volume: 30
  start-page: 1038
  year: 2009
  ident: 10.1016/j.cjca.2023.10.013_bib74
  article-title: Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehn579
– volume: 396
  start-page: 1079
  year: 2020
  ident: 10.1016/j.cjca.2023.10.013_bib41
  article-title: Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)31791-8
– volume: 327
  start-page: 1585
  year: 2022
  ident: 10.1016/j.cjca.2023.10.013_bib9
  article-title: Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US preventive services task force
  publication-title: JAMA
  doi: 10.1001/jama.2022.3337
– volume: 357
  start-page: 2001
  year: 2007
  ident: 10.1016/j.cjca.2023.10.013_bib32
  article-title: Prasugrel versus clopidogrel in patients with acute coronary syndromes
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0706482
– volume: 36
  start-page: 856
  year: 2009
  ident: 10.1016/j.cjca.2023.10.013_bib64
  article-title: Postoperative blood loss in patients undergoing coronary artery bypass surgery after preoperative treatment with clopidogrel. A prospective randomised controlled study
  publication-title: Eur J Cardiothorac Surg
  doi: 10.1016/j.ejcts.2009.05.032
– volume: 251
  start-page: 70
  year: 2022
  ident: 10.1016/j.cjca.2023.10.013_bib38
  article-title: Rationale and design of switch Swedeheart: a registry-based, stepped-wedge, cluster-randomized, open-label multicenter trial to compare prasugrel and ticagrelor for treatment of patients with acute coronary syndrome
  publication-title: Am Heart J
  doi: 10.1016/j.ahj.2022.05.017
– volume: 41
  start-page: 1625
  year: 2020
  ident: 10.1016/j.cjca.2023.10.013_bib45
  article-title: Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehz821
– volume: 342
  start-page: d3527
  year: 2011
  ident: 10.1016/j.cjca.2023.10.013_bib43
  article-title: Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial
  publication-title: BMJ
  doi: 10.1136/bmj.d3527
– volume: 57
  start-page: 672
  year: 2011
  ident: 10.1016/j.cjca.2023.10.013_bib61
  article-title: Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2010.10.029
– volume: 10
  start-page: 1
  year: 2021
  ident: 10.1016/j.cjca.2023.10.013_bib62
  article-title: Platelet quiescence in patients with acute coronary syndrome undergoing coronary artery bypass graft surgery
  publication-title: J Am Heart Assoc
– volume: 16
  start-page: 798
  year: 2023
  ident: 10.1016/j.cjca.2023.10.013_bib22
  article-title: Abbreviated or standard antiplatelet therapy in HBR patients: final 15-month results of the MASTER-DAPT trial
  publication-title: JACC Cardiovasc Interv
  doi: 10.1016/j.jcin.2023.01.366
– volume: 358
  start-page: 527
  year: 2001
  ident: 10.1016/j.cjca.2023.10.013_bib52
  article-title: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(01)05701-4
– volume: 73
  start-page: 741
  year: 2019
  ident: 10.1016/j.cjca.2023.10.013_bib15
  article-title: Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2018.11.048
– volume: 35
  start-page: 107
  year: 2019
  ident: 10.1016/j.cjca.2023.10.013_bib49
  article-title: 2019 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Guidelines on the acute management of ST-elevation myocardial infarction: focused update on regionalization and reperfusion
  publication-title: Can J Cardiol
  doi: 10.1016/j.cjca.2018.11.031
– volume: 56
  start-page: 550
  year: 2010
  ident: 10.1016/j.cjca.2023.10.013_bib54
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2010.01.067
– volume: 141
  start-page: 1618
  year: 2020
  ident: 10.1016/j.cjca.2023.10.013_bib78
  article-title: Risk/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.120.046534
– volume: 381
  start-page: 1524
  year: 2019
  ident: 10.1016/j.cjca.2023.10.013_bib34
  article-title: Ticagrelor or prasugrel in patients with acute coronary syndromes
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1908973
– volume: 148
  start-page: 989
  year: 2023
  ident: 10.1016/j.cjca.2023.10.013_bib31
  article-title: Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: a randomized, open-label clinical trial
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.123.065448
– volume: 76
  start-page: 162
  year: 2020
  ident: 10.1016/j.cjca.2023.10.013_bib11
  article-title: Post-discharge bleeding and mortality following acute coronary syndromes with or without PCI
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2020.05.031
– volume: 394
  start-page: 1335
  year: 2019
  ident: 10.1016/j.cjca.2023.10.013_bib77
  article-title: Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(19)31872-0
– volume: 14
  year: 2021
  ident: 10.1016/j.cjca.2023.10.013_bib55
  article-title: Pretreatment with P2Y12 inhibitors in patients with chronic coronary syndrome undergoing percutaneous coronary intervention: a report from the Swedish Coronary Angiography and Angioplasty Registry
  publication-title: Circ Cardiovasc Interv
  doi: 10.1161/CIRCINTERVENTIONS.121.010849
– volume: 120
  start-page: 2577
  year: 2009
  ident: 10.1016/j.cjca.2023.10.013_bib63
  article-title: Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.109.912550
– volume: 382
  start-page: 1981
  year: 2013
  ident: 10.1016/j.cjca.2023.10.013_bib84
  article-title: Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data
  publication-title: Lancet
  doi: 10.1016/S0140-6736(13)61615-3
– volume: 4
  start-page: 747
  year: 2019
  ident: 10.1016/j.cjca.2023.10.013_bib75
  article-title: Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials
  publication-title: JAMA Cardiol
  doi: 10.1001/jamacardio.2019.1880
– volume: 382
  start-page: 1960
  year: 2013
  ident: 10.1016/j.cjca.2023.10.013_bib85
  article-title: Cangrelor: a new CHAMPION for percutaneous coronary intervention
  publication-title: Lancet
  doi: 10.1016/S0140-6736(13)61840-1
– volume: 107
  start-page: 1145
  year: 2021
  ident: 10.1016/j.cjca.2023.10.013_bib35
  article-title: Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention
  publication-title: Heart
  doi: 10.1136/heartjnl-2020-318694
– volume: 371
  start-page: 1016
  year: 2014
  ident: 10.1016/j.cjca.2023.10.013_bib46
  article-title: Prehospital ticagrelor in ST-segment elevation myocardial infarction
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1407024
– volume: 139
  start-page: 604
  year: 2019
  ident: 10.1016/j.cjca.2023.10.013_bib79
  article-title: Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.118.036768
– volume: 290
  start-page: 59
  year: 2019
  ident: 10.1016/j.cjca.2023.10.013_bib18
  article-title: Risk of contrast-induced nephropathy in patients undergoing complex percutaneous coronary intervention
  publication-title: Int J Cardiol
  doi: 10.1016/j.ijcard.2019.04.043
– volume: 111
  start-page: 2099
  year: 2005
  ident: 10.1016/j.cjca.2023.10.013_bib58
  publication-title: Circulation
  doi: 10.1161/01.CIR.0000161383.06692.D4
– volume: 71
  start-page: 371
  year: 2018
  ident: 10.1016/j.cjca.2023.10.013_bib37
  article-title: 1-Year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2017.11.008
– volume: 377
  start-page: 1319
  year: 2017
  ident: 10.1016/j.cjca.2023.10.013_bib82
  article-title: Rivaroxaban with or without aspirin in stable cardiovascular disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1709118
– volume: 5
  start-page: 881
  year: 2023
  ident: 10.1016/j.cjca.2023.10.013_bib8
  article-title: Aspirin for the primary prevention of vascular ischemic events: an updated systematic review and meta-analysis to support shared decision-making
  publication-title: CJC Open
  doi: 10.1016/j.cjco.2023.08.011
– volume: 379
  start-page: 1499
  year: 2018
  ident: 10.1016/j.cjca.2023.10.013_bib4
  article-title: Effect of aspirin on disability-free survival in the healthy elderly
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1800722
– volume: 37
  start-page: 189
  year: 2016
  ident: 10.1016/j.cjca.2023.10.013_bib66
  article-title: Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehv381
– volume: 29
  start-page: 1334
  year: 2013
  ident: 10.1016/j.cjca.2023.10.013_bib2
  article-title: Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy
  publication-title: Can J Cardiol
  doi: 10.1016/j.cjca.2013.07.001
– volume: 398
  start-page: 1305
  year: 2021
  ident: 10.1016/j.cjca.2023.10.013_bib40
  article-title: Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)01445-8
– volume: 13
  year: 2020
  ident: 10.1016/j.cjca.2023.10.013_bib57
  article-title: Randomized comparison of intensified and standard P2Y12-receptor-inhibition before elective percutaneous coronary intervention: the SASSICAIA trial
  publication-title: Circ Cardiovasc Interv
  doi: 10.1161/CIRCINTERVENTIONS.119.008649
– volume: 1
  year: 2022
  ident: 10.1016/j.cjca.2023.10.013_bib68
  article-title: Bentracimab for ticagrelor reversal in patients undergoing urgent surgery
  publication-title: NEJM Evid
  doi: 10.1056/EVIDoa2100047
– volume: 34
  start-page: 214
  year: 2018
  ident: 10.1016/j.cjca.2023.10.013_bib3
  article-title: 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy
  publication-title: Can J Cardiol
  doi: 10.1016/j.cjca.2017.12.012
– volume: 1
  start-page: 921
  year: 2016
  ident: 10.1016/j.cjca.2023.10.013_bib67
  article-title: Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting
  publication-title: JAMA Cardiol
  doi: 10.1001/jamacardio.2016.3028
– volume: 36
  start-page: 1847
  year: 2020
  ident: 10.1016/j.cjca.2023.10.013_bib81
  article-title: The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation
  publication-title: Can J Cardiol
  doi: 10.1016/j.cjca.2020.09.001
– volume: 382
  start-page: 1208
  year: 2020
  ident: 10.1016/j.cjca.2023.10.013_bib12
  article-title: Polymer-based or polymer-free stents in patients at high bleeding risk
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1910021
– year: 2023
  ident: 10.1016/j.cjca.2023.10.013_bib23
  article-title: An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial [epub ahead of press]
  publication-title: Circulation
– volume: 38
  start-page: 3070
  year: 2017
  ident: 10.1016/j.cjca.2023.10.013_bib39
  article-title: Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehx175
– volume: 369
  start-page: 999
  year: 2013
  ident: 10.1016/j.cjca.2023.10.013_bib50
  article-title: Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1308075
– volume: 82
  start-page: 89
  year: 2023
  ident: 10.1016/j.cjca.2023.10.013_bib27
  article-title: P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2023.04.051
– volume: 134
  start-page: 1603
  year: 2016
  ident: 10.1016/j.cjca.2023.10.013_bib36
  article-title: Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.116.024823
– volume: 101
  start-page: 305
  year: 2012
  ident: 10.1016/j.cjca.2023.10.013_bib48
  article-title: Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial
  publication-title: Clin Res Cardiol
  doi: 10.1007/s00392-011-0393-1
– volume: 147
  start-page: 1933
  year: 2023
  ident: 10.1016/j.cjca.2023.10.013_bib28
  article-title: Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the Academic Research Consortium
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.123.064473
– volume: 76
  start-page: 2450
  year: 2020
  ident: 10.1016/j.cjca.2023.10.013_bib51
  article-title: Timing of oral P2Y12 inhibitor administration in patients with non-ST-segment elevation acute coronary syndrome
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2020.08.053
– volume: 140
  start-page: 240
  year: 2019
  ident: 10.1016/j.cjca.2023.10.013_bib14
  article-title: Defining high bleeding risk in patients undergoing percutaneous coronary intervention
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.119.040167
– volume: 18
  year: 2023
  ident: 10.1016/j.cjca.2023.10.013_bib24
  article-title: Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: systematic review and meta-analysis
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0291061
– volume: 27
  start-page: S1
  issue: suppl A
  year: 2011
  ident: 10.1016/j.cjca.2023.10.013_bib1
  article-title: The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines
  publication-title: Can J Cardiol
  doi: 10.1016/j.cjca.2010.12.015
– volume: 29
  start-page: 204
  year: 2013
  ident: 10.1016/j.cjca.2023.10.013_bib73
  article-title: Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention/stenting: a systematic review and meta-analysis
  publication-title: Can J Cardiol
  doi: 10.1016/j.cjca.2012.06.012
– volume: 371
  start-page: 2155
  year: 2014
  ident: 10.1016/j.cjca.2023.10.013_bib29
  article-title: Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1409312
– volume: 31
  start-page: 354
  year: 2020
  ident: 10.1016/j.cjca.2023.10.013_bib69
  article-title: Antiplatelet therapy and coronary artery bypass grafting: a systematic review and network meta-analysis
  publication-title: Interact Cardiovasc Thorac Surg
  doi: 10.1093/icvts/ivaa115
– volume: 348
  start-page: 1329
  year: 1996
  ident: 10.1016/j.cjca.2023.10.013_bib26
  article-title: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee
  publication-title: Lancet
  doi: 10.1016/S0140-6736(96)09457-3
– ident: 10.1016/j.cjca.2023.10.013_bib65
– volume: 2
  year: 2023
  ident: 10.1016/j.cjca.2023.10.013_bib10
  article-title: Aspirin with or without statin in individuals without atherosclerotic cardiovascular disease across risk categories
  publication-title: JACC Adv
  doi: 10.1016/j.jacadv.2022.100197
– volume: 367
  start-page: l5476
  year: 2019
  ident: 10.1016/j.cjca.2023.10.013_bib70
  article-title: Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis
  publication-title: BMJ
  doi: 10.1136/bmj.l5476
– volume: 384
  start-page: 216
  year: 2021
  ident: 10.1016/j.cjca.2023.10.013_bib7
  article-title: Polypill with or without aspirin in persons without cardiovascular disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2028220
– volume: 54
  start-page: 1438
  year: 2009
  ident: 10.1016/j.cjca.2023.10.013_bib59
  article-title: Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2009.06.021
– volume: 107
  start-page: 966
  year: 2003
  ident: 10.1016/j.cjca.2023.10.013_bib53
  article-title: Early and late effects of clopidogrel in patients with acute coronary syndromes
  publication-title: Circulation
  doi: 10.1161/01.CIR.0000051362.96946.15
– volume: 367
  start-page: 1297
  year: 2012
  ident: 10.1016/j.cjca.2023.10.013_bib42
  article-title: Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1205512
– reference: 38740360 - Can J Cardiol. 2024 May 10;:
SSID ssj0041776
Score 2.502925
Snippet Antiplatelet therapy (APT) is the foundation of treatment and prevention of atherothrombotic events in patients with atherosclerotic cardiovascular disease....
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 160
SubjectTerms Acute Coronary Syndrome - drug therapy
Canada
Cardiology
Humans
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors
Systematic Reviews as Topic
Treatment Outcome
Title Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology 2023 Focused Update of the Guidelines for the Use of Antiplatelet Therapy
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0828282X2301841X
https://dx.doi.org/10.1016/j.cjca.2023.10.013
https://www.ncbi.nlm.nih.gov/pubmed/38104631
https://www.proquest.com/docview/2903323902
Volume 40
WOSCitedRecordID wos001187960200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals 2021
  customDbUrl:
  eissn: 1916-7075
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0041776
  issn: 0828-282X
  databaseCode: AIEXJ
  dateStart: 20171101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6DSFeEHfKZTISb1VKE-f6WMo2LmJC0Ep5ixLHllq6tLTNtP0WfiP_gXNiO0mLNi4SL2nl2HHa88U-dr7zHUJe-n7mMZkLS2QDz4IBT1qpZLnFctdxZQ4Liiitkk0Ep6dhHEefOp0fJhbmfB4URXhxES3_q6mhDIyNobN_Ye76olAA38HocASzw_GPDF_rDYy2qaaan4mCuKZGyzYmpGTVcNBV-0qiCbOf944XvFyDfzpZ4i6BIReclCiUheT5mrE4Ue8HhgVSFaEqQAOZHbV6wa4wQku9gtd9NlusU01I-wBzeNH73G820VffyunaOsEMSipPWIk5lMqzhimAryUurRHSAV67G8UKqIb_s-l8WlcbY2x4LTTw9bL3pt_eDXFcQ6A2W3QmTGeLRYoyfRasLeP2sK9UojS8ndYYbqsEB9odsFVGmV9mGrXpMevzGUf5Kof1kSSo4mp3FLy_YP_YPSz3YEFtx3vkwAm8CAbhg-G7o_i9cR1cO6iyIdb3q6O8FCFxt6erPKmrVkqVxzS-Q27rpQ4dKojeJR1R3CM3P2oyx33y3QCAbiOVaqS-qs-3cEoXkm7jlDY4pXjfVOOUKpxiAwAlbXBKAadVEeAUz7ZxSjVOH5DJ8dF49NbSuUIs7g6CjWVHARe-yPMMHFjPDzku7EUqXXB5A-6EPPfDyA4GgrkykzyUMBLJIIUPm2dZmLOHZL9YFOIxoUxmThT6LOW26_KURaEUTgqegRhkLPe8LrHN_55wLaSP-VzmiWFMzhK0VYK_GcvAVl3Sq9sslYzMtbWZMWdiAqRhSk8Ae9e28upW2n1WbvFv270wiElgbsEXhmkhFuU6caIBYw6LBk6XPFJQqu8elQFdn9lP_rHXp-RW8_w-I_ubVSmekxv8fDNdrw7JXhCHh_rx-AlNvwMz
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Canadian+Cardiovascular+Society%2FCanadian+Association+of+Interventional+Cardiology+2023+Focused+Update+of+the+Guidelines+for+the+Use+of+Antiplatelet+Therapy&rft.jtitle=Canadian+journal+of+cardiology&rft.au=Bainey%2C+Kevin+R.&rft.au=Marquis-Gravel%2C+Guillaume&rft.au=Belley-C%C3%B4t%C3%A9%2C+Emilie&rft.au=Turgeon%2C+Ricky+D.&rft.date=2024-02-01&rft.pub=Elsevier+Inc&rft.issn=0828-282X&rft.volume=40&rft.issue=2&rft.spage=160&rft.epage=181&rft_id=info:doi/10.1016%2Fj.cjca.2023.10.013&rft.externalDocID=S0828282X2301841X
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0828-282X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0828-282X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0828-282X&client=summon